Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 138

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 138
---
 implement screening and due diligence processes when selecting third -partyinfrastructure providers, ensuring alignment with industry best practices and relevant healthcare regulations. We aim to regularly monitor and assess third -partytechnologies for performance, security, and compliance, as well as the AI industry landscape. Where necessary, adjustments or replacements to these infrastructures may occur to ensure the safety, accuracy, and reliability of our AI Agents. Furthermore, maintaining human oversight where appropriate is a priority, integrating medical professionals into the process when a human touch is required, to ensure our AI solutions continue to meet high standards of care and regulatory compliance. Finally, the regulatory environment for AI in healthcare is evolving, with growing scrutiny around data privacy, transparency, and accountability. As our AI Agents process sensitive health data, we face risks related to compliance with diverse and emerging regulations. Failure to meet these standards, or any data breach resulting from either our own systems or third -partyinfrastructure, could lead to regulatory penalties, reputational damage, and financial losses. Additional Risks Related to the Business Combination SPAC has no operating or financial history and its results of operations and those of the Combined Company may differ significantly from the unaudited pro forma financial data included in this proxy statement. SPAC has no operating history and no revenues. This proxy statement/prospectus includes unaudited pro forma condensed combined consolidated statements of financial position and unaudited pro forma combined consolidated statements of operations for the year ended June 30, 2024 for OmnigenicsAI and SPAC. The unaudited pro forma combined consolidated statements of financial position as of June 30, 2024 combine the audited combined statements of financial position of OmnigenicsAI as of June 30, 2024, and the unaudited balance sheet of SPAC as of June 30, 2024 on a pro forma basis as if the Business Combination had been consummated on June 30, 2024. The unaudited pro forma combined consolidated statements of operations for the year ended June 30, 2024, combine the historical audited combined statements of operations of OmnigenicsAI for year ended June 30, 2024, and the historical statement of operations of SPAC for the twelve -monthperiod ended June 30, 2024 using its unaudited statements of operations for the six -monthperiod ended June 30, 2024 together with its audited statements of operations for the fiscal year ended December 31, 2023, deducting its